FDA unveils drugs to receive expedited review in support of ‘national priorities’
October 16, 2025
The Food and Drug Administration is announcing the first round of drugs that will receive drastically expedited reviews at the agency. It’s part of an effort by the Trump administration to prioritize medicines that are seen as supporting U.S. national interests. The nine drugs announced by the agency include a potential treatment for people undergoing infertility treatments. President Donald Trump has pledged to lower costs for those treatments since his days on the campaign trail. Until now, the fastest FDA reviews took at least six months. That’s for groundbreaking drugs to treat life-threatening diseases. Under the new initiative, the FDA is aiming to review the designated drugs in one or two months.